Key points are not available for this paper at this time.
A phase 3 open-label extension study (OLES) to evaluate long-term safety/tolerability of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) in patients with Parkinson's disease (PD).
Fung et al. (Tue,) studied this question.